Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
Abstract
Chronic kidney disease (CKD) is common and ranks among the leading causes of mortality and morbidity. This analysis aimed to present global CKD estimates using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 to inform evidence-based policies for CKD identification and treatment.
This analysis focused on adults aged 20 years and older over the period 1990 to 2023, from 204 countries and territories. Data sources used were published literature, vital registration systems, kidney failure treatment registries, and household surveys. Estimates of CKD burden, including deaths, incidence, prevalence, and disability-adjusted life-years (DALYs), were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool. A comparative risk assessment approach estimated the proportion of cardiovascular deaths attributable to impaired kidney function and estimated risk factors for CKD.
Citation impact
- FWCI
- 110.43
- Percentile
- 100%
- References
- 31
Authors
597Topics & keywords
- Kidney disease
- Burden of disease
- Diabetes mellitus
- Disease burden
- Attributable risk
- Disease
- Risk assessment
Funding
- BABill and Melinda Gates Foundation
- NKNational Kidney Foundation
- AAmgen
- ELEli Lilly and Company
- AAstraZeneca
- SSanofi
- BBiogen
- RPRegeneron Pharmaceuticals
- WTWellcome TrustAwards: 301005/Z/23/Z, 221854, 221854/Z/20/Z
- UPUltragenyx Pharmaceutical
- ACAmarin Corporation
- NCNational Cerebral and Cardiovascular Center
- GOGovernment of Canada
- CUCardiff University
- AAAustralian Academy of Science
- FCFondazione Cariplo
- NNNovo Nordisk
- MDMinistério da Ciência, Tecnologia e Ensino SuperiorAward: UIDP/50006/2020
- UDUniversidade do Porto
- SServier
- RDRede de Química e TecnologiaAward: UIDP/50006/2020
- LALaboratório Associado para a Química VerdeAward: UIDP/50006/2020
- ETEsperion Therapeutics
- NINational Institutes of Health
- CICanadian Institutes of Health Research
- MRMedical Research CouncilAwards: MR/Y014154/1, Y014154
- JSJapan Society for the Promotion of ScienceAwards: 50006, 301005, P23712
- FPFundação para a Ciência e a TecnologiaAward: UIDP/50006/2020
- NINational Institute of Diabetes and Digestive and Kidney DiseasesAward: R01DK100446
- DSDaiichi Sankyo Europe